We are here to assist you.
Health Advisor
+91-8877772277Available 7 days a week
10:00 AM – 6:00 PM to support you with urgent concerns and guide you toward the right care.
A detailed guide to Xifaxan (rifaximin), covering its uses for traveler's diarrhea, IBS-D, and hepatic encephalopathy, along with dosage information, how to take it, and important precautions for Indian readers.
Xifaxan, with the active ingredient rifaximin, is a prescription antibiotic medication used to treat specific gastrointestinal conditions. It is available in tablet form and is typically taken orally. This guide provides a detailed overview of Xifaxan's uses, dosages, and important considerations for patients in India.
Xifaxan is an antibiotic that works by targeting bacteria in the gut. Its primary uses include:
The dosage of Xifaxan is determined by your doctor based on the specific condition being treated. It is crucial to follow your doctor's prescription precisely. Xifaxan tablets are available in two strengths: 200 mg and 550 mg.
For adults and children aged 12 years and older diagnosed with traveler's diarrhea caused by specific E. coli strains, the typical dosage is:
This is a short-term treatment course. If you experience bloody diarrhea or fever, Xifaxan will not be prescribed, and your doctor will recommend an alternative treatment.
For IBS-D, the common dosage regimen is:
If your symptoms return after the initial treatment, your doctor may advise repeating this 14-day course up to two additional times. This treatment is also for a limited duration.
To reduce the risk of recurring hepatic encephalopathy episodes, the recommended dosage is:
This dosage is typically for longer-term management as prescribed by your doctor.
Xifaxan comes as a tablet that you swallow whole. It can be taken with or without food. There are no specific dietary restrictions required while taking Xifaxan. However, if you are experiencing diarrhea, it is essential to maintain adequate hydration by drinking plenty of fluids.
Always take Xifaxan exactly as prescribed by your doctor. Do not alter the dosage or stop the medication without consulting your healthcare provider.
If you suspect you have taken too much Xifaxan, contact your doctor immediately. You can also reach out to local poison control centers for guidance. In case of severe symptoms, call emergency services or go to the nearest emergency room.
Studies have shown that rifaximin (the active ingredient in Xifaxan) can be effective in treating Small Intestinal Bacterial Overgrowth (SIBO). In clinical trials, a significant percentage of individuals treated with rifaximin experienced resolution of SIBO symptoms.
It is essential to consult a doctor if:
This information is intended for educational purposes and should not replace professional medical advice. Always consult with a qualified healthcare provider for any health concerns or before making any decisions related to your health or treatment.
This section adds practical context and preventive advice to help readers make informed healthcare decisions. It is important to verify symptoms early, consult qualified doctors, and avoid self-medication for persistent health issues.
Maintaining healthy routines, following prescribed treatment plans, and attending regular checkups can improve outcomes. If symptoms worsen or red-flag signs appear, immediate medical evaluation is recommended.
Track symptoms and duration.
Follow diagnosis and treatment from a licensed practitioner.
Review medication side effects with your doctor.
Seek urgent care for severe warning signs.
Confused about whether CBD can get you high? Understand the difference between CBD and THC, their effects on your body, and what to look for in safe, non-intoxicating CBD products.
April 1, 2026
Learn about anticoagulants and antiplatelet drugs, often called blood thinners. Understand how they prevent blood clots, when they're prescribed, their side effects, and essential safety tips for Indian readers.
April 1, 2026

Confused about Plan B and abortion pills? Understand the key differences, how they work, and their effectiveness for informed reproductive health decisions.
April 1, 2026